New sirolimus balloon takes on paclitaxel in leg artery showdown
NCT ID NCT07359807
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two drug-coated balloons for treating narrowed or blocked arteries in the leg. The experimental balloon uses sirolimus, a drug that stops cells from growing and blocking the artery again, while the standard balloon uses paclitaxel. About 478 people with leg artery disease will be randomly assigned to one of the two balloons. The main goal is to see if the sirolimus balloon keeps arteries open just as well as the paclitaxel balloon after one year, with fewer complications.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sirolimus (drug-coated balloon)
What this could lead to
If it works, this could offer a better option for opening blocked leg arteries, potentially reducing the need for repeat procedures.
What could go wrong
This is an early-to-mid-stage trial (Phase 2/3) with 478 participants, so results may not apply to everyone. The sirolimus balloon might not be as effective or safe as the standard paclitaxel balloon.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POPLITEAL ARTERY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••